Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03093805 · ClinicalTrials.gov registry record · NA
Topical Vitamin D in Acute Graft Versus Host Disease of the Skin
A NA study of Graft Vs Host Disease, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03093805: Completed NA study of Graft Vs Host Disease, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT03093805 is a NA study of Graft Vs Host Disease that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 10 participants, below the 138-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03093805, a NA study of Graft Vs Host Disease, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy of Calcipotriene cream. This is a synthetic vitamin D3 derivative for topical use. It is used to treat grade 1-3 acute skin graft versus host disease (GVHD) in hematopoietic stem cell transplant (HSCT) recipients. Calcipotriene will be used as the exclusive topical therapy in addition to standard of care GVHD treatment prescribed for the study subject by the primary physician.
Primary Outcome
Change in GVHD grade over 7 days. GVHD grade based on Glucksberg criteria
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Calcipotriene
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2019-03-26 |
| Phase | NA |
What the finished NCT03093805 record still lists
NCT03093805 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 138-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Graft Vs Host Disease appearing as the primary indexed condition, and to 1 intervention - of which Calcipotriene is the first listed.
NCT03093805 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03093805 about?
NCT03093805 is a clinical study titled "Topical Vitamin D in Acute Graft Versus Host Disease of the Skin". The purpose of this study is to evaluate the efficacy of Calcipotriene cream. This is a synthetic vitamin D3 derivative for topical use. It is used to treat grade 1-3 acute skin graft versus host disease (GVHD) in hematopoietic stem cell transplant (HSCT) recipients. Calcipotriene will be used as th...
What is the current status of trial NCT03093805?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2017-03-15. Estimated completion is 2019-03-26.
What conditions does trial NCT03093805 study?
This clinical trial studies the following conditions: Graft Vs Host Disease.
What interventions are being tested in trial NCT03093805?
The interventions under investigation include: Calcipotriene (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03093805?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03093805 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03093805's enrollment target sits among peer trials
10 36th of 36 the lowest of 36 other Graft Vs Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graft Vs Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
RECRUITING · NA
-
A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
RECRUITING · NA
-
Horizons Chronic Graft-Versus-Host-Disease Study
ACTIVE NOT RECRUITING · NA
-
Multidisciplinary Intervention In Chronic GVHD
ACTIVE NOT RECRUITING · NA
-
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
ACTIVE NOT RECRUITING · NA
-
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI